

Steve Vucic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6378692/publications.pdf>

Version: 2024-02-01

74
papers

6,225
citations

117625
34
h-index

88630
70
g-index

74
all docs

74
docs citations

74
times ranked

5852
citing authors

#	ARTICLE	IF	CITATIONS
1	Amyotrophic lateral sclerosis. Lancet, The, 2011, 377, 942-955.	13.7	2,182
2	Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain, 2008, 131, 1540-1550.	7.6	391
3	Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain, 2006, 129, 2436-2446.	7.6	284
4	TDP-43 proteinopathies: a new wave of neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 86-95.	1.9	174
5	Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Nature Reviews Neurology, 2016, 12, 651-661.	10.1	165
6	Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurology, The, 2015, 14, 478-484.	10.2	164
7	Assessment of cortical excitability using threshold tracking techniques. Muscle and Nerve, 2006, 33, 477-486.	2.2	162
8	Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2021, 17, 104-118.	10.1	152
9	Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clinical Neurophysiology, 2015, 126, 803-809.	1.5	140
10	Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain, 2013, 136, 1361-1370.	7.6	123
11	Rate of disease progression: a prognostic biomarker in ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 628-632.	1.9	123
12	Cortical excitability distinguishes ALS from mimic disorders. Clinical Neurophysiology, 2011, 122, 1860-1866.	1.5	122
13	Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis. JAMA Neurology, 2018, 75, 681.	9.0	120
14	Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 849-852.	1.9	97
15	Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clinical Neurophysiology, 2013, 124, 410-416.	1.5	97
16	Upregulation of persistent sodium conductances in familial ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 222-227.	1.9	86
17	Motor cortical function determines prognosis in sporadic ALS. Neurology, 2016, 87, 513-520.	1.1	76
18	Cortical Dysfunction Underlies the Development of the Split-Hand in Amyotrophic Lateral Sclerosis. PLoS ONE, 2014, 9, e87124.	2.5	75

#	ARTICLE	IF	CITATIONS
19	Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: A systematic review using individual patient data. <i>Clinical Neurophysiology</i> , 2016, 127, 2684-2691.	1.5	74
20	Physiological changes in neurodegeneration – mechanistic insights and clinical utility. <i>Nature Reviews Neurology</i> , 2018, 14, 259-271.	10.1	72
21	Diagnostic Utility of Gold Coast Criteria in <scp>Amyotrophic Lateral Sclerosis</scp>. <i>Annals of Neurology</i> , 2021, 89, 979-986.	5.3	68
22	Imbalance of cortical facilitatory and inhibitory circuits underlies hyperexcitability in ALS. <i>Neurology</i> , 2018, 91, e1669-e1676.	1.1	67
23	Measurement of axonal excitability: Consensus guidelines. <i>Clinical Neurophysiology</i> , 2020, 131, 308-323.	1.5	63
24	Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2016, 17, 580-588.	1.7	58
25	Utility of threshold tracking transcranial magnetic stimulation in ALS. <i>Clinical Neurophysiology Practice</i> , 2018, 3, 164-172.	1.4	51
26	Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. <i>BMJ Open</i> , 2016, 6, e012054.	1.9	48
27	Neurophysiological index as a biomarker for ALS progression: Validity of mixed effects models. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011, 12, 33-38.	2.1	47
28	FOSMN syndrome. <i>Neurology</i> , 2012, 79, 73-79.	1.1	47
29	Dissociated lower limb muscle involvement in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2015, 262, 1424-1432.	3.6	47
30	Split-hand plus sign in ALS: Differential involvement of the flexor pollicis longus and intrinsic hand muscles. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 315-318.	1.7	46
31	Diagnostic criteria in amyotrophic lateral sclerosis. <i>Neurology</i> , 2016, 87, 684-690.	1.1	46
32	Cortical hyperexcitability evolves with disease progression in ALS. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 733-741.	3.7	45
33	ALS pathophysiology: Insights from the split-hand phenomenon. <i>Clinical Neurophysiology</i> , 2014, 125, 186-193.	1.5	44
34	ALS is a multistep process in South Korean, Japanese, and Australian patients. <i>Neurology</i> , 2020, 94, e1657-e1663.	1.1	39
35	Neurofascin-155 IGG4 Neuropathy: Pathophysiological Insights, Spectrum of Clinical Severity and Response To treatment. <i>Muscle and Nerve</i> , 2018, 57, 848-851.	2.2	37
36	Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 668-678.	1.9	35

#	ARTICLE	IF	CITATIONS
37	The evolution of motor cortical dysfunction in amyotrophic lateral sclerosis. <i>Clinical Neurophysiology</i> , 2017, 128, 1075-1082.	1.5	34
38	Inter-session reliability of short-interval intracortical inhibition measured by threshold tracking TMS. <i>Neuroscience Letters</i> , 2018, 674, 18-23.	2.1	34
39	Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression. <i>BMJ Open</i> , 2021, 11, e041479.	1.9	33
40	Physiological Processes Underlying Short Interval Intracortical Facilitation in the Human Motor Cortex. <i>Frontiers in Neuroscience</i> , 2018, 12, 240.	2.8	31
41	Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. <i>Brain</i> , 2010, 133, 2727-2733.	7.6	29
42	Motor neurone disease: progress and challenges. <i>Medical Journal of Australia</i> , 2017, 206, 357-362.	1.7	28
43	Pathophysiologic insights into motor axonal function in Kennedy disease. <i>Neurology</i> , 2007, 69, 1828-1835.	1.1	27
44	Cortical hyperexcitability and the split-hand plus phenomenon: Pathophysiological insights in ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2014, 15, 250-256.	1.7	27
45	Split-hand and split-limb phenomena in amyotrophic lateral sclerosis: pathophysiology, electrophysiology and clinical manifestations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1126-1130.	1.9	25
46	Functional Biomarkers for Amyotrophic Lateral Sclerosis. <i>Frontiers in Neurology</i> , 2018, 9, 1141.	2.4	23
47	Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study). <i>Medicine (United States)</i> , 2020, 99, e18904.	1.0	23
48	Cortical excitability differences in hand muscles follow a split-hand pattern in healthy controls. <i>Muscle and Nerve</i> , 2014, 49, 836-844.	2.2	22
49	Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1147-1154.	2.8	22
50	Amyotrophic lateral sclerosis as a multi-step process: an Australia population study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 532-537.	1.7	22
51	Regional motor cortex dysfunction in amyotrophic lateral sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1373-1382.	3.7	19
52	Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1991-1999.	3.7	18
53	Reproducibility of motor unit number index and MScanFit motor unit number estimation across intrinsic hand muscles. <i>Muscle and Nerve</i> , 2020, 62, 192-200.	2.2	17
54	Gold Coast diagnostic criteria: Implications for <sc>ALS</sc> diagnosis and clinical trial enrollment. <i>Muscle and Nerve</i> , 2021, 64, 532-537.	2.2	16

#	ARTICLE	IF	CITATIONS
55	Anti-MAG neuropathy: Role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels. <i>Clinical Neurophysiology</i> , 2018, 129, 2162-2169.	1.5	15
56	Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. <i>Muscle and Nerve</i> , 2021, 63, 371-383.	2.2	13
57	Pathophysiological associations of transcallosal dysfunction in ALS. <i>European Journal of Neurology</i> , 2021, 28, 1172-1180.	3.3	12
58	Association of Cortical Hyperexcitability and Cognitive Impairment in Patients With Amyotrophic Lateral Sclerosis. <i>Neurology</i> , 2021, 96, e2090-e2097.	1.1	12
59	Split elbow sign: more evidence for the importance of cortical dysfunction in ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 729-729.	1.9	10
60	Review Article "Spotlight on Ultrasonography in the Diagnosis of Peripheral Nerve Disease: The Evidence to Date". <i>International Journal of General Medicine</i> , 2021, Volume 14, 4579-4604.	1.8	7
61	Posturography as a biomarker of intravenous immunoglobulin efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Muscle and Nerve</i> , 2022, 65, 43-50.	2.2	6
62	Long read sequencing overcomes challenges in the diagnosis of SORD neuropathy. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 120-126.	3.1	6
63	Autosomal recessive hereditary spastic paraparesis with thin corpus callosum; report of two sisters. <i>Journal of Clinical Neuroscience</i> , 2004, 11, 427-430.	1.5	4
64	Utility of Transcranial Magnetic Stimulation in Studying Upper Motor Neuron Dysfunction in Amyotrophic Lateral Sclerosis. <i>Brain Sciences</i> , 2021, 11, 906.	2.3	4
65	MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 321-328.	1.7	4
66	The split-elbow index: A biomarker of the split elbow sign in ALS. <i>Clinical Neurophysiology Practice</i> , 2022, 7, 16-20.	1.4	4
67	The Upper Motor Neuron "Improved Knowledge from ALS and Related Clinical Disorders. <i>Brain Sciences</i> , 2021, 11, 958.	2.3	3
68	Chronic inflammatory demyelinating polyneuropathy after commencement of dupilumab for atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 105-106.	1.0	3
69	Nerve biopsy in acquired neuropathies. <i>Journal of the Peripheral Nervous System</i> , 2021, 26 Suppl 2, S21-S41.	3.1	2
70	Electrodiagnostic findings in facial onset sensory motor neuronopathy (FOSMN). <i>Clinical Neurophysiology</i> , 2022, 140, 228-238.	1.5	2
71	P300 jitter latency, brain-computer interface and amyotrophic lateral sclerosis. <i>Clinical Neurophysiology</i> , 2021, 132, 614-615.	1.5	1
72	Split-hand sign: clinical feature of spinal bulbar muscular atrophy?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1143-1144.	1.9	0

#	ARTICLE	IF	CITATIONS
73	Neurotoxicity and ALS: Insights into Pathogenesis. , 2021,, 1-19.		0
74	Advances in the understanding of sensory neuronopathies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 343-343.	1.9	0